title: 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.
abstract: This is the first in a series of practice guidelines commissioned by the Infectious Diseases Society of America through its Practice Guidelines Committee. The purpose of these guidelines is to provide assistance to clinicians when making decisions on treating the conditions specified in each guideline. The targeted providers are internists, pediatricians, and family practitioners. The targeted patients and setting for the fever and neutropenia guideline are hospitalized individuals with neutropenia secondary to cancer chemotherapy. Panel members represented experts in adult and pediatric infectious diseases and oncology. The guidelines are evidence-based. A standard ranking system was used for the strength of the recommendations and the quality of the evidence cited in the literature reviewed. The document has been subjected to external review by peer reviewers as well as by the Practice Guidelines Committee and was approved by the IDSA Council. An executive summary, algorithms, and tables highlight the major recommendations. The guideline will be listed on the IDSA home page at http://www.idsociety.org.
authors.affiliation: Fever and Neutropenia Guideline Panel, Infectious Diseases Society of America, Alexandria, Virginia, USA.
authors.forename: W T
authors.initials: WT
authors.lastname: Hughes
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: G P
authors.initials: GP
authors.lastname: Bodey
authors.forename: A E
authors.initials: AE
authors.lastname: Brown
authors.forename: J E
authors.initials: JE
authors.lastname: Edwards
authors.forename: R
authors.initials: R
authors.lastname: Feld
authors.forename: P
authors.initials: P
authors.lastname: Pizzo
authors.forename: K V
authors.initials: KV
authors.lastname: Rolston
authors.forename: J L
authors.initials: JL
authors.lastname: Shenep
authors.forename: L S
authors.initials: LS
authors.lastname: Young
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002648:Child; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005335:Fever of Unknown Origin / Q000150:complications* / Q000188:drug therapy*; D006098:Granulocytes / Q000637:transplantation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D003115:Colony-Stimulating Factors